The present invention provides a PD-L1 antibody pharmaceutical composition anduse thereof. In particular, the presentinvention provides a pharmaceutical composition comprising the PD-L1 antibodyor an antigen-binding fragment thereof in a succinatebuffer. In addition, the pharmaceutical composition may also contain a sugarand a nonionic surfactant.